When Merck & Co., Inc. (NYSE: MRK) released its fourth-quarter financial results after the markets closed on Thursday, the pharma giant said that it had $1.04 in earnings per share (EPS) and $11 billion in revenue. That compared with consensus estimates of $1.03 in EPS and $10.94 billion in revenue, as well as the $0.98 per share and $10.43 billion posted in the same period of last year.
In the latest quarter, worldwide sales increased 5% from the fourth quarter of 2017, including a 3% negative impact from foreign exchange.
Keytruda, the firm’s main cancer treatment, brought in $2.15 billion in the quarter, up 88% year over year. It generated $7.17 billion in 2018, up by the same percentage, and now accounts for more than 20% of the company’s revenue.
Growth in oncology was driven by a significant increase in sales of Keytruda, reflecting the strong momentum for the treatment of patients with non-small cell lung cancer and the company’s continued launches with new indications globally.
Merck reported on a few of the major products as follows:
- Januvia/Janumet net sales decreased 4% to $1.47 billion.
- Gardasil/Gardasil 9 net sales increased 32% to $835 million.
- Proquad, M-M-R II and Varivax net sales increased 13% to $455 million.
- Pneumovax 23 net sales increased 23% to $322 million.
- Isentress/Isentress HD net sales decreased 9% to $280 million.
Looking ahead to the 2019 full year, the firm expects to see EPS in the range of $4.57 to $4.72 and worldwide sales between $43.2 billion and $44.7 billion. Consensus estimates call for $4.69 in EPS and $44.54 billion in revenue for the year.
Kenneth C. Frazier, board chair and chief executive of Merck, commented:
Last year was a strong one for Merck marked by substantial progress on scientific and commercial fronts. The fourth-quarter and full-year results further bolster our confidence in Merck’s innovation-based strategy in which our key pillars – oncology, vaccines, animal health, and select hospital and specialty care products – are expected to drive sustainable growth over the long-term. We enter 2019 with good momentum, anticipating the many opportunities afforded by our broad and differentiated portfolio and pipeline.
Shares of Merck closed Thursday at $74.43, in a 52-week range of $52.83 to $80.19. The consensus price target is $82.09. Following the announcement, the stock was up about 2.6% at $76.41 in early trading indications Friday.
24/7 Wall St.Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
